Barclays Maintains Overweight on Abbott Laboratories, Lowers Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Abbott Laboratories (ABT) but lowers the price target from $141 to $140.
April 22, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays maintains an Overweight rating on Abbott Laboratories but lowers the price target from $141 to $140.
The slight adjustment in price target by Barclays reflects a nuanced view on Abbott Laboratories' valuation, without changing the overall positive outlook. This minor adjustment is unlikely to have a significant short-term impact on the stock price, but it indicates a slight recalibration of expectations by the analyst.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100